Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults
Official title: A Randomized, Open, Two-sequence, Crossover, Multiple Oral Administrations, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Drug-drug Interaction Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
Key Details
Gender
All
Age Range
19 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2024-10-26
Completion Date
2025-04-01
Last Updated
2024-10-16
Healthy Volunteers
Yes
Conditions
Interventions
DWP16001 0.3mg
1 tablet, Orally, Once daily single dose
DWC202407 1,000mg
1 tablet, Orally, Twice daily
DWC202408 2mg
1 tablet, Orally, Once daily single dose
Locations (1)
Seoul National University Hospital
Seoul, South Korea